Macclesfield-based MPM produces high-quality, natural pet foods for discerning cat and dog owners. Within the global pet food market, estimated to be worth £50 billion, the premium niche has been taking market share, helping to drive market value growth in an otherwise low growth category.
Investors 1
| Date | Name | Website |
| - | ECI Partne... | ecipartner... |
Mentions in press and media 22
| Date | Title | Description | Source |
| 01.06.2023 | Reunion Neuroscience Announces US$13.1 Million Take-Private ... | - | globenewsw... |
| 06.10.2021 | MPM Capital Raises $850 Million to Fund Cancer Drug Firms M... | - | bloombergq... |
| 27.02.2020 | MPM Capital raises $100m Oncology Innovations Fund | Healthcare venture firm MPM Capital has raised $100m for its MPM Oncology Innovations Fund, in colla... | altassets.... |
| 26.02.2020 | MPM gains first offer on Dana-Farber tech, raises $100M fund... | MPM Capital and Dana-Farber Cancer Institute have formed a venture philanthropy alliance, raising a ... | fiercebiot... |
| 20.11.2019 | MPM and Longwood-backed Werewolf Therapeutics grabs $56... | Backed with the team from his last company, one of the key developers behind Keytruda has a n... | endpts.com... |
| 22.02.2019 | MPM Capital raises $400M in seventh venture fund | “Over two decades of investing, MPM has developed long-standing and strategic partners with academia... | medcitynew... |
| 21.02.2019 | MPM Capital secures $400M treasure chest for early biotechs ... | Life science VC MPM Capital is looking to boost funding for a select series of early-stage biotechs ... | fiercebiot... |
| 21.02.2019 | Scrip Pharma intelligence: MPM Raises $400M To Build Early-S... | - | mpmcapital... |
| 21.02.2019 | MPM Capital closes bioventure fund on $400m | Healthcare-focused VC MPM Capital has ended its seventh fundraise after pulling in $400m for its Bio... | altassets.... |
| 21.02.2019 | MPM Capital secures $400M treasure chest for early biotechs | Life science VC MPM Capital is looking to boost funding for a select series of early-stage biotechs ... | fiercebiot... |
Show more